Beclanorsen is an antisense oligonucleotide targeted to the mRNA of the Bcl-2 oncoprotein.

Beclanorsen sodium is an antisense oligonucleotide targeted to the mRNA of the Bcl-2 oncoprotein.

Bazlitoran, an oligonucleotide, is an antagonist of TLR7, TLR8, and TLR9.

Bazlitoran sodium, an oligonucleotide, is an antagonist of TLR7, TLR8, and TLR9.

Archexin is an antisense oligonucleotide (ASO) against Akt1. It is used for the study of metastatic renal cancer.

Archexin sodium is an antisense oligonucleotide (ASO) against Akt1. It is used for the study of metastatic renal cancer.

ARC5690 sodium is an anti-mouse P-selectin aptamer. ARC5690 bound to recombinant mouse P-selectin with a KD of approximately 15pM in vitro. ARC5690 showed a significant anti-inflammatory effect

aptTNF-α sodium is a TNF-α-targeting aptamer that has tissue protective effect and systemic anti-inflammatory effect upon acute tissue injury using the mouse acute lung injury (ALI) and acute liver failure (ALF) models.

Apazunersen is an antisense oligonucleotide (ASO) that targets and inhibits expression of the UBE3A antisense transcript (UBE3A-AS) to prevent silencing of the paternally inherited allele of the UBE3A gene and reactivate expression of the deficient protei

Apazunersen sodium is an antisense oligonucleotide (ASO) that targets and inhibits expression of the UBE3A antisense transcript (UBE3A-AS) to prevent silencing of the paternally inherited allele of the UBE3A gene and reactivate expression of the deficient

ALN-3133 sodium is a siRNA that targets VEGF, and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for kinesin spindle protein (KSP) and VEGF with potential antitumor activity.

ALN-12115 is a siRNA that targets kinesin spindle protein (KSP), and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for KSP and VEGF with potential antitumor activity.

ALN-12115 sodium is a siRNA that targets kinesin spindle protein (KSP), and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for KSP and VEGF with potential antitumor activity.

AGN-745 is a chemically modified siRNA targeted to VEGFR-1. It is used for the study of Macular degeneration.

AGN-745 sodium is a chemically modified siRNA targeted to VEGFR-1. It is used for the study of Macular degeneration.

Agazisiran, a siRNA,is a complement factor B synthesis reducer.

Agazisiran sodium, a siRNA,is a complement factor B synthesis reducer.

Afovirsen is a 20-mer phosphorothioate oligonucleotide. It is complementary to the mRNA sequence for the translation initiation codon of the E2 protein vital to replication of HPV types 6 and 11.

Afovirsen sodium is a 20-mer phosphorothioate oligonucleotide. It is complementary to the mRNA sequence for the translation initiation codon of the E2 protein vital to replication of HPV types 6 and 11.

A9g sodium is an RNA aptamer that inhibits the enzymatic activity of prostate-specific membrane antigen (PSMA).

148.1-38m sodium, an RNA aptamer, inhibits HIV-1 reverse transcriptase (RT) and interfere with viral replication.

Calderasib (MK-1084) is a selective KRAS G12C inhibitor demonstrating antitumor efficacy. It can be utilized as monotherapy or in combination with pembrolizumab () for oncology research.

Cephalexin (hydrochloride, Cefalexin hydrochloride) is a potent, orally active cephalosporin antibiotic with broad-spectrum activity. It acts by binding to penicillin-binding proteins (PBPs), thereby disrupting bacterial cell wall synthesis. Cephalexin hydrochloride demonstrates antibacterial activity against a wide variety of gram-positive and gram-negative bacteria.

Emzadirib, an inhibitor of RAD51, exhibits a reduction in RAD51 foci. This compound displays significant anti-tumor activity with tumor growth inhibition in in vivo and in vitro models.

Ribociclib succinate hydrate is an orally bioavailable and selective, inhibitor of both CDK4 and CDK6 with IC50 values of 10 nM and 39 nM, respectively. It exhibits anticancer activitiy and can be used in breast cancer, melanoma, liposarcoma, non–small cell lung cancer, and neuroblastoma therapy research.

PolQi2 is a PolΘ inhibitor that specifically targets the N-terminal helicase domain of PolΘ, thereby suppressing alt-EJ (alternative end-joining) repair. This compound improves the accuracy and integration efficiency of gene editing across multiple loci and diverse cell lines. Additionally, it demonstrates synergistic effects with DNA-PK inhibitors in reducing Cas9-mediated off-target activity. Its application is suitable for gene editing studies.

RMC5127 is a first-in-class, orally bioavailable mutant-selective tri-complex inhibitor of the GTP-bound (ON) form of RASG12V. It non-covalently binds to cyclophilin A (CypA), forming a binary complex that engages RASG12V(ON) to form a high-affinity tri-complex, sterically inhibiting RAS binding. It inhibits the RAS pathway in KRASG12V-mutant cancer cells, reducing proliferation, inducing apoptosis, and showing strong potential for use in RASG12V-mutated cancer research.

TNG348 is an orally bioavailable allosteric inhibitor targeting the ubiquitin-specific protease USP1. It selectively and potently blocks USP1 activity, preventing deubiquitination of proliferative PCNA and FANCD2, which disrupts DNA repair mechanisms. TNG348 demonstrates inhibitory effects against BRCA1/2-mutated and homologous recombination-deficient (HRD) breast and ovarian cancers .

BI033 is a selective inhibitor of BTB and CNC homology 1 (BACH1) specifically binds to BACH1's N-terminal with a Kd of 9.0 uM. It disrupts the BACH1–HDAC1 interaction, enhances H3K27 acetylation at BACH1 target genes, and upregulates angiogenic genes, suggesting its therapeutic potential for myocardial infarction and ischemic vascular disease.

Peptide 4 is a complex synthetic peptide molecule commonly used as a research chemical or therapeutic agent due to its potential to mimic biological peptides and modulate specific molecular targets.